Oculus Innovative Sciences, Inc. (Nasdaq: OCLS) a healthcare company that designs, produces and markets innovative, safe and effective anti-infective products and medical devices while also developing multiple drug candidates, today announced the issuance of new U.S. patent for the use of Microcyn® Technology in the treatment of skin ulcers. In this application, Microcyn Technology can be delivered to skin ulcers via washing, irrigation and soaking or through application of a wound dressing saturated in the Microcyn Technology.

According to claims allowed by the patent examiner, the application of the Microcyn Technology via these methods will:

Reduce the microbial load of an infected diabetic foot ulcer

Decrease the recurrence rate of an infected diabetic foot ulcer

Decrease the likelihood of dehiscence of an infected diabetic foot ulcer

Decrease the likelihood of amputation resulting from an infected diabetic foot ulcer

Decrease the likelihood of systemic inflammatory response syndrome from an infected diabetic foot ulcer

Decrease the likelihood of sepsis

(c) 2012 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. Copyright 2013 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.